Live feed08:00:00·28dPRReleaseMeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational ResultsMGTX· MeiraGTx Holdings plcHealth CareOriginal source
